Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients

<div>(a) Sensitivity of the microarray assays. A ~ D were four dilutions from 1 × 102 to 1 × 105 CFU/mL for plasmid bacteria and E was blank control, F ~ I were 10 ng /μL, 5 ng /μL, 2 ng /μL, and 1 ng /μL for human genomic DNA. (b) 23S rRNA reference plasmids (1 × 102 to 1 × 105 CFU/mL) were detected by the real-time PCR and (c) gyrA reference plasmids (1 × 102 to 1 × 105 CFU/mL) were detected by the real-time PCR.</div>

BioMed Research International

fig3

Figure 3

Figure 3: Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients

Figure 3 | Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients 